Autosomal Dominant Polycystic Kidney Disease – Understanding the Disease and Improving Treatment Adherence and Outcome
Released On
June 30, 2024
Expires On
June 30, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Acute Care, Cardiology, Gastroenterology, Genetics, Hepatology, Hospitalist, Neurology, Nephrology, Nutrition, Pain Management, Pharmacy, Primary Care, Radiology, Surgery, Urology
Topic(s)
Kidney Disease, Nutrition, Pharmacology, Radiology
This activity is jointly provided by P2P Syncro and Partners for Advancing Clinical Education.
This activity is supported by an independent educational grant from Otsuka Pharmaceuticals.
Credit Available
- Physicians — maximum of 1 AMA PRA Category 1 Credits™
- Nurses — 1 Nursing Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of nephrologists, primary care providers, and providers who care for patients with kidney disease.
Program Overview
In the real-world setting, treatment adherence in patients with autosomal dominant polycystic kidney disease (ADPKD) can be a challenge. This CME program will discuss the diagnosis and management of ADPKD as well as strategies on improving treatment adherence. Patients’ perspectives on how to deal with aquaresis-related symptoms will be shared.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the problem of lack of adherence to therapy in patients with ADPKD in the real-world.
- Identify barriers for treatment initiation and risk for treatment discontinuation in clinical practice.
- Develop evidence-based strategies to counter the aquaretic effect from disease modifying therapy.
Faculty
Neera Dahl, MD PhD
Dr. Dahl is a nephrologist and the Director of the PKD Foundation Center of Excellence at Mayo Clinic, Rochester, MN. She is a nationally recognized expert in the field of autosomal dominant polycystic kidney disease (ADPKD).
Navin Gupta, MD
Dr. Gupta is a nephrologist at Mayo Clinic, Rochester, MN. He has extensive experience in the diagnosis and management of ADPKD. His translational research work is supported by the National Institute of Health.
Elyssa Noce, DNP, APRN
Dr. Noce is a nephrology nurse practitioner at Yale-New Haven Hospital in New Haven, CT, where provides care for patients across the spectrum of renal diseases. She is a core member of the PKD Foundation Center of Excellence program at Yale, where she provides expertise in the holistic care of patients with ADPKD, including patient counseling and medication management. She is also a lecturer in the master’s program at Yale University.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and P2P Syncro. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-24-137-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosures of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
- Dr. Neera K. Dahl, faculty for this educational activity, has the following relevant financial relationships:
- Consultant, Advisor, or Speaker : Otsuka, Natera, Vertex, PYC Therap., Renasant Bio
- Research support : Regulus and Vertex
- Dr. Navin Rath Gupta, faculty for this activity, has no relevant financial relationships.
- Dr. Elyssa Noce, DNP, faculty for this activity, has the following relevant financial relationships:
- Consultant, Advisor, or Speaker : Otsuka and Bayer
- Other: PKD Foundation (ADPKD Education Advisory Panel)
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from June 28, 2024 through June 28, 2025
- Review the objectives and disclosures
- Study the educational content
- Complete activity post-test(s)
- Complete the activity evaluation
You must respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com.